Recap: Bladder Cancer Treatment Algorithm

Opinion
Video

The Oncology Brothers recap the discussion on treatment practices for patients with bladder cancer.

Recent Videos
Considering which non–muscle-invasive bladder cancer cases may be cured by surgery alone may help mitigate overtreatment in this patient group.
Event-free survival benefit was observed among BCG-naïve patients with carcinoma in situ undergoing treatment with sasanlimab plus BCG.
Comprehensive prehabilitation may help prepare patients for bladder-preserving surgery, helping to optimize quality of life outcomes.
Ongoing research suggests environmental exposures and the role of microbiomes may influence bladder cancer development and response to treatment.
Other ongoing urothelial cancer trials are assessing enfortumab vedotin–based combinations in the neoadjuvant setting.
Approximately 95% of those with a complete response to enfortumab vedotin plus pembrolizumab were alive after 2 years in the phase 3 EV-302 trial.
Thomas Powles, MBBS, MRCP, MD, highlighted fatigue, nausea, and peripheral neuropathy as toxicities observed with enfortumab vedotin plus pembrolizumab.
Related Content
Detalimogene voraplasmid demonstrated a 71% any-time CR rate in this non-muscle invasive bladder cancer population in the phase 1/2 LEGEND trial.

FDA Grants RMAT Designation to Detalimogene in BCG-Unresponsive NMIBC

Tim Cortese
June 26th 2025
Article

Detalimogene voraplasmid demonstrated a 71% any-time CR rate in this non-muscle invasive bladder cancer population in the phase 1/2 LEGEND trial.

NIAGARA Study is the Forefront of Post-ASCO GU Discussion in Bladder Cancer

NIAGARA Study is the Forefront of Post-ASCO GU Discussion in Bladder Cancer

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Petros Grivas, MD, PhD;David Morris, MD, MS
March 4th 2025
Podcast

The Oncology Decoded podcast highlighted the impact of the results from the NIAGARA trial for patients with bladder cancer in a post-ASCO GU discussion.

Data from the ENVISION trial may support UGN-102 as a well-tolerated, efficacious treatment in non–muscle-invasive bladder cancer.

Robust Responses Occur With UGN-102 in Recurrent Intermediate-Risk NMIBC

Gina Mauro
June 11th 2025
Article

Data from the ENVISION trial may support UGN-102 as a well-tolerated, efficacious treatment in non–muscle-invasive bladder cancer.

Jun Gong, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on elderly patients with muscle-invasive bladder cancer.

Oncology Peer Review On-The-Go: Neoadjuvant Chemotherapy for Elderly Patients with Muscle-Invasive Bladder Cancer

Matthew Fowler;Jun Gong, MD
March 15th 2022
Podcast

Jun Gong, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on elderly patients with muscle-invasive bladder cancer.

Sasanlimab Combo Poised to Change High-Risk NMIBC Treatment Paradigm

Sasanlimab Combo Poised to Change High-Risk NMIBC Treatment Paradigm

Ben Saylor
May 31st 2025
Article

Sasanlimab plus BCG significantly improved event-free survival in BCG-naïve, high-risk NMIBC patients, with notable benefit in carcinoma in situ and T1 tumors.

"Given the superior efficacy of [chemoimmunotherapy], it holds promise as a first-line neoadjuvant therapy for MIBC, providing greater benefits to patients," according to the study authors.

Chemoimmunotherapy Boosts Pathological Complete Responses in MIBC

Russ Conroy
May 24th 2025
Article

Real-world data may support chemotherapy plus immune checkpoint blockade as a promising frontline neoadjuvant therapy for muscle-invasive bladder cancer.